[Smoking and changes in body weight: can physiopathology and genetics explain this association?].
Tobacco use is the leading preventable cause of death in most countries, including Brazil. Smoking cessation is an important strategy for reducing the morbidity and mortality associated with tobacco-related diseases. An inverse relationship between nicotine use and body weight has been reported, in which body weight tends to be lower among smokers than among nonsmokers. Smoking abstinence results in an increase in body weight for both males and females. On average, sustained quitters gain from 5 to 6 kg, although approximately 10% gain more than 10 kg. Pharmacological treatment for smoking cessation attenuates weight gain. The importance of smoking cessation as a contributing cause of the current obesity epidemic has been little studied. In the USA, the rate of obesity attributable to smoking cessation has been estimated at approximately 6.0 and 3.2% for males and females, respectively. Although the mechanisms are unclear, there is evidence that dopamine and serotonin are appetite suppressants. The administration of nicotine, regardless of the delivery system, acutely raises the levels of these neurotransmitters in the brain, reducing the need for energy intake and consequently suppressing appetite. In addition, nicotine has a direct effect on adipose tissue metabolism, influencing the rate of weight gain following smoking cessation. Leptin, ghrelin and neuropeptide Y are substances that might constitute factors involved in the inverse relationship between nicotine and body mass index, although their roles as determinants or consequences of this relationship have yet to be determined.
Chatkin
Raquel
R
Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brasil.
Chatkin
José Miguel
JM
D001069:Appetite Regulation / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D005260:Female; D054439:Ghrelin / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006815:Hunger / Q000187:drug effects / Q000502:physiology; D020738:Leptin / Q000235:genetics / Q000378:metabolism; D008297:Male; D009478:Neuropeptide Y / Q000235:genetics / Q000378:metabolism; D009538:Nicotine / Q000009:adverse effects*; D009765:Obesity / Q000209:etiology / Q000517:prevention & control; D011110:Polymorphism, Genetic / Q000187:drug effects / Q000235:genetics; D012309:Risk-Taking; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects / Q000188:drug therapy / Q000503:physiopathology*; D016540:Smoking Cessation; D015430:Weight Gain / Q000187:drug effects / Q000235:genetics / Q000502:physiology
D054439:Ghrelin; D020738:Leptin; D009478:Neuropeptide Y; D009538:Nicotine